Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.57 |
| ▸ | CLPP | Q16740 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4237925 | 1.00 | GRM5 (0.57) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL4233395 | 0.92 | PDE2A (0.48) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL4233388 | 0.92 | PDE2A (0.48) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL4233149 | 0.88 | GRM5 (0.55) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL4235342 | 0.88 | GRM5 (0.55) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL4232189 | 0.86 | GRM5 (0.68) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL412929 | 0.86 | GRM5 (0.68) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL4233384 | 0.86 | GRM5 (0.68) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL4637025 | 0.86 | HSD11B1 (0.51) | GRM5CLPPMEN1KMT2APOLB | |
| SCHEMBL4232221 | 0.85 | GRM5 (0.54) | GRM5CLPPATML3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NIKEM RESEARCH SRL (IT) | 2009-08-27 | — | — | US | claimed |
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NIKEM RESEARCH SRL (IT) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM3, GRM2 | GRM5 1/4885CLPP 4652/4885ATM 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.